Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06832189 · ClinicalTrials.gov registry record · Phase 1

EVR and EPO for Liver Transplant Tolerance

A Phase 1 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
3
Study locations

NCT06832189 is a Phase 1 study of Liver Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 20 participants, below the 5,457-participant average among 19 other Liver Transplant trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06832189, a Phase 1 study of Liver Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
3
Study locations

Study Summary

This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR. The primary objective is to test the safety of administering Everolimus (EVR) and epoetin alfa (EPO) to induce operational tolerance in stable adult liver transplant recipients

Conditions Studied

Liver Transplant

Interventions

  • DRUG Everolimus
  • DRUG Epoetin alfa

Study Locations (3)

California

  • University of California San Francisco School of Medicine - San Francisco

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago

Pennsylvania

  • University of Pennsylvania Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-01-21
Est. Completion 2030-06-01
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06832189

The ClinicalTrials.gov registry entry for NCT06832189 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,457-participant average among 19 other Liver Transplant trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.

NCT06832189 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06832189 about?

NCT06832189 is a clinical study titled "EVR and EPO for Liver Transplant Tolerance". This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR. The ...

What is the current status of trial NCT06832189?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-21. Estimated completion is 2030-06-01.

What conditions does trial NCT06832189 study?

This clinical trial studies the following conditions: Liver Transplant.

What interventions are being tested in trial NCT06832189?

The interventions under investigation include: Everolimus (DRUG), Epoetin alfa (DRUG).

Who is sponsoring clinical trial NCT06832189?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06832189 being conducted?

This trial has 3 study locations across California, Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Transplant

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.